New Drug Reduces MS Relapses In Patients

A new drug undergoing a two year phase III TEMSO trial show very good results in the treatment of relapsing multiple Sclerosis. The said drug, called teriflunomide, has significantly reduced the yearly relapse rate by 31 percent as compared to a placebo. The results of the trial also showed a significant reduction on the risk of disability progression by 30 percent when taking 14mg of the said drug and 24 percent for the 7mg dose.

Teriflunomide is a new disease modifying drug being tested by French pharmaceutical company Sanofi-Aventis as a possible treatment for relapsing MS. It is eyed as a possible oral therapy for relapsing MS. According to Marc Cluzel, M.D., Ph.D. And executive vice president for Research And Development for Sanofi-Aventis, “These exciting results with teriflunomide represent a new real hope to delivering an oral therapy to patients who live with this serious condition and are eager for new treatment options, and more convenient product forms in-line with our Sanofi-Aventis commitment to multiple sclerosis.”

The said drug has undergone a TEMSO trial, which was a two year randomized, double-blind, placebo-controlled multinational study that involved 1,088 participants from 21 countries with relapsing MS and with ages ranging 18 to 55 years old. The participants also experienced at least one relapse during the previous year . Participants were randomly given a placebo or teriflunomide in either 7mg or 14mg doses once daily for 108 weeks.

The results showed a significant reduction in relapse rate in patients with MS. Other results showed a significantly reduced brain disease activity as shown by MRI measures. Total lesion volume decreased by 39 percent and 67 percent with teriflunomide in 7mg and 14mg doses, respectively, as compared to a placebo. Additional findings showed that teriflunomide was also well tolerated by patients and had no major safety concerns.

Source: http://www.medicalnewstoday.com/articles/204838.php

 
You can leave a response, or trackback from your own site.